Safety of Active Immunotherapy in Subjects With Ovarian Cancer
Recruitment status was: Active, not recruiting
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase I, Open, Randomized, Study to Investigate the Safety of Active Immunotherapy With Fully Mature, TERT-mRNA and Survivin - Peptide Double Loaded Dendritic Cells (DCs) in Subjects With Advanced Epithelial Ovarian Cancer, Enrolled in the Study Within Twelve Weeks After Completing Primary Therapy|
- Incidence of Adverse Events and clinical relevant deviations from Laboratory parameters [ Time Frame: from first treatment until up to 12 to 19 weeks ]
- Number of circulating tumor cells in peripheral blood [ Time Frame: from first treatment till up to 12 to 19 weeks ]Circulating tumor cells (CTCs) will be quantified prior vaccination and follow up. CTCs will be enriched from peripheral blood and characterized by specific biomarkers. Quantitation of CTCs will provide information about the stage of a malignancy, onset of disease progression and response of therapy.
- Immune monitoring - Number of autologous dendritic cells loaded with tumor specific antigens [ Time Frame: from first treatment until treatment visit 7 up to 12 weeks ]Immune monitoring will be done prior vaccination and during treatment. The immune reaction of the patients will be surveyed by determination of the frequency of specific markers for T-Cells, activated T-cells,B-cells,NK (Natural Killer)-cells, NKT (Natural Killer T)-cells.Quantification of these cells will be done by multicolour FACS (Florescence activated cell sorting). This method will be applied to determine the effects of dendritic cell treatment on the patients immune system.
- time to progression (CA (Cancer Antigen)-125 and CT (Computer tomography) [ Time Frame: from first treatment until up to 12 to 19 weeks ]
- Overall survival [ Time Frame: from first treatment until up to 96 weeks ]
|Study Start Date:||September 2010|
|Estimated Study Completion Date:||April 2013|
|Estimated Primary Completion Date:||April 2013 (Final data collection date for primary outcome measure)|
|Vaccine weekly administration||
The IMP (Investigational Medical Product) consists of 1.3*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO (Dimethyl sulfoxide), solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial. 8 vial will be injected on weekly administration basis to the patient.
|Vaccine biweekly administration||
The IMP consists of 1.3*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO, solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial, 8 vials will be injected into the patient on biweekly basis.
This is an uncontrolled, randomized, parallel-group, open-label phase I trial in patients with advanced epithelial ovarian cancer. Patients were randomized into treatment group A with weekly administration versus treatment group B with bi-weekly administration.
Patients in both treatment groups received a maximum of eight injections administered one by one once a week for eight times for treatment group A and once in a fortnight for eight times for treatment group B.
The treatment was completed within seven weeks for Arm A and within 14 weeks for Arm B. Independently of the treatment arm they had been assigned to, all the patients were followed for a period covering a total of 12 or 19 weeks or until disease progression. Safety parameters (primary objective) and efficacy parameters (secondary objective) were recorded. Upon completion of the treatment, one follow-up visit took place at week 12 (group A, only) or 19 (group B, only).
To protect the patients' safety, the first six patients were treated as described below:
- The first patient was hospitalized and kept under medical observation for 72h after administration of the first and second dose of the investigational product;
- After an observational period of 3 days following the second dose of the first patient, the second and the third patient were administered the first dose of the investigational product, hospitalized and kept under medical observation for 72h. The two patients were treated simultaneously or consecutively;
- After an observational period of 3 days after the second dose to the first three patients, an interim safety report was sent to the Ethics Committee;
Additionally the next three patients were hospitalized, administered their first dose of the vaccine and kept under medical observation for 72h. The three patients were treated simultaneously or consecutively.
15 evaluable patients (which were randomized to one of the two treatment groups in equal numbers) 5 study sites in Austria and Hungary
Please refer to this study by its ClinicalTrials.gov identifier: NCT01456065
|Hospital Landeskrankenhaus Innsbruck|
|Innsbruck, Austria, 6020|
|Korneuburg, Austria, 2100|
|Hospital Barmherzigen Schwestern|
|Linz, Austria, 4010|
|Budapest, Hungary, 1083|
|National Oncology Institute|
|Budapest, Hungary, 1122|
|Principal Investigator:||Martin Imhof, Dr.||Hospital Korneuburg|